Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.

Inclusion Criteria:

1. Participants who completed the 48-week treatment period of DRI16762 study, includingEOT visit, as per protocol

2. Participants with stable background therapy of moderate to high ICS therapy (≥500 µg/day to 2000 µg/day fluticasone propionate or equivalent ICS dosage daily) incombination with at least 1 but no more than 2 additional controller medications (eg, LABA, LAMA, LTRA, or methylxanthines) with or without oral prednisone asmaintained during the parent study in which they have participated

3. Participants who are able and willing to participate in the open-label extensionstudy, and to comply with requested study visits and procedures

4. Contraception for male and female participants For female participants:

• must agree to use contraception/barrier

• not pregnant or breast feeding

• no eggs donation or cryopreserving eggs For male participants:

• No sperm donation or cryopreserving sperm

5. Capable of giving signed informed consent

Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

1. Participant who developed a new medical condition or a change in status of anestablished medical condition or requires a new treatment or medication prior toenrollment that, per Investigator's medical judgement would adversely affectparticipation of the participant in this study or would require permanent lunsekimigdiscontinuation, or participants potentially at risk of noncompliance to studyprocedures

2. Participant who was diagnosed with a new pulmonary disease which may impair lungfunction

3. Current smoker or active vaping of any products and/or marijuana smoking

4. Prescription drug or substance abuse, including alcohol, considered significant bythe Investigator

5. History of hypersensitivity or allergy to lunsekimig or to any of the excipientsused in the presentation or in preparation for administration of lunsekimig, orother allergy that, in the opinion of the Investigator, contraindicatesparticipation in the study

6. Participants who are receiving prohibited concomitant medications

7. Participants who, during their participation in the parent study, developed an AE oran SAE deemed related to lunsekimig, which in the opinion of the Investigator couldindicate that continued treatment with lunsekimig may present an unreasonable riskfor the participant

8. Concurrent participation in any other clinical study, including non-interventionalstudies

9. Individuals accommodated in an institution because of regulatory or legal order;prisoners or participants who are legally institutionalized

10. Participants are employees of the investigative site or other individuals directlyinvolved in the conduct of the study, or immediate family members of suchindividuals.